{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:46:09Z","timestamp":1786718769906,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/aja.aja_39_17","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:38:25Z","timestamp":1510015105000},"page":"184","source":"Crossref","is-referenced-by-count":11,"title":["External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer"],"prefix":"10.4103","volume":"20","author":[{"given":"Bo","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Wei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu-Yang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.217782-1","first-page":"7\u201330","volume-title":"Cancer statistics, 2016","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/1008-682X.217782-2","first-page":"1502\u201312","volume-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.217782-3","first-page":"411\u201322","volume-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.217782-4","first-page":"213\u201323","volume-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.217782-5","first-page":"1187\u201397","volume-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.217782-6","first-page":"1995\u20132005","volume-title":"Abiraterone and increased survival in metastatic prostate cancer","author":"de","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.217782-7","first-page":"138\u201348","volume-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.217782-8","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae). Prostate Cancer. Ver. 1.2017. National Comprehensive Cancer Network Website; 2017. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. [Last accessed on 2016 Dec 16]."},{"key":"key-10.4103\/1008-682X.217782-9","first-page":"454\u201360","volume-title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","author":"Chi","year":"2016","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1008-682X.217782-10","first-page":"8\u201311","volume-title":"External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone","author":"Ravi","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.217782-11","first-page":"1148\u201359","volume-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.217782-12","first-page":"205\u201316","volume-title":"New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1008-682X.217782-13","first-page":"2109\u201323","volume-title":"Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation","author":"Pencina","year":"2004","journal-title":"Stat Med"},{"key":"key-10.4103\/1008-682X.217782-14","first-page":"128\u201338","volume-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"key-10.4103\/1008-682X.217782-15","first-page":"2927\u201341","volume-title":"American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer","author":"Loblaw","year":"2004","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.217782-16","first-page":"915\u201320","volume-title":"Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation","author":"Salonen","year":"2008","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.217782-17","first-page":"594\u2013605","volume-title":"Castration-resistant prostate cancer: from new pathophysiology to new treatment targets","author":"Chi","year":"2009","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.217782-18","first-page":"983\u201392","volume-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.217782-19","first-page":"152\u201360","volume-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.217782-20","first-page":"3972\u201382","volume-title":"Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration","author":"Smaletz","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.217782-21","first-page":"1232\u20137","volume-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1008-682X.217782-22","first-page":"595\u2013601","volume-title":"Clinical characteristics and prognostic factors of prostate cancer with liver metastases","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"key":"key-10.4103\/1008-682X.217782-23","first-page":"73\u201380","volume-title":"Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma","author":"Sagnak","year":"2011","journal-title":"Clin Genitourin Cancer"},{"key":"key-10.4103\/1008-682X.217782-24","unstructured":"Martinez-Cornelio A, Gonzalez-Perez J, Tabares-Garcia FJ, Ramos-Salgado F, Alvarado-Cabrero I, et al. [Androgen-deprivation therapy in the management of neuroendocrine prostate cancer]. Cir Cir 2009; 77: 293\u20139, 273\u20138. [Article in English, Spanish]."},{"key":"key-10.4103\/1008-682X.217782-25","first-page":"566\u20137","volume-title":"Factors affecting the accuracy of prediction models limit the comparison of rival prediction models when applied to separate data sets","author":"Kattan","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.217782-26","first-page":"1142\u201351","volume-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement","author":"Collins","year":"2015","journal-title":"Eur Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:39:34Z","timestamp":1786714774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja.aja_39_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"alternative-id":["217782"],"URL":"https:\/\/doi.org\/10.4103\/aja.aja_39_17","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}